$CON

Concentra (CON) Q2 2026 Earnings Call Transcript

Concentra Group Holdings Parent (CON) reported Q2 2026 revenue of $606 million (+10% YoY) and adjusted EBITDA of $140.9 million (+22.5%), with adjusted EPS of $0.52. Management raised full-year guidance: revenue to $2.325B-$2.375B and adjusted EBITDA to $485M-$495M. Net leverage fell to 2.99x. A CEO transition to Matt DiCanio takes effect Nov. 1, 2026.

Original reporting
Published Aug 14, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Concentra (CON) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CONBullishHigh
01

Why it matters

The key tradable items are the raised full-year guidance ranges, the improved net leverage ratio ahead of schedule, and the declared dividend, all tied to stronger-than-expected Q2 performance.

02

Market read

Traders can update FY 2026 expectations immediately using the raised revenue, EBITDA, and free cash flow guidance plus the sub-3.0x leverage milestone.

03

What to watch

Margin seasonality in the second half and slower workers' comp visit growth versus Q1 could offset the leverage and cash flow improvements if rates normalize faster than expected.

Relevance 9/10Novelty 9/10Timing: pre-market/early trading after Aug. 7 call transcript publication

Background

Concentra held its Q2 2026 earnings call, covering operating metrics, cash flow, leverage, guidance, and a planned CEO succession.

Company-level read

Ticker impact

$CONBullishMedium confidence
Context

Concentra reported Q2 2026 results and raised full-year 2026 revenue, adjusted EBITDA, and free cash flow guidance, plus declared a dividend.

Expected impact

Likely positive bias for CON as traders reprice FY 2026 cash flow and leverage trajectory; follow-through depends on how much of the guide raise is rate-driven vs sustainable volume.

Evidence & confidence

The article provides multiple hard datapoints: raised revenue to $2.325B-$2.375B, raised adj. EBITDA to $485M-$495M, raised FCF to $220M-$240M, and reduced net leverage to 2.99x, all of which are direct valuation inputs.

Market effects

Occupational health and workers' compensation service providers may see read-across demand for rate-driven margin expansion and visit growth durability.

State-specific workers' comp rate bumps (notably California and Tennessee) highlight regional policy sensitivity for peers with similar exposure.

Limited direct global linkage; primarily a US healthcare services and workers' comp reimbursement story.

Counterpoint

Guidance upside may be heavily dependent on state rate increases and favorable visit mix, which management expects to moderate later in the year.

Key entities

  • Concentra Group Holdings Parent, Inc.

    Reported Q2 2026 results and raised FY 2026 guidance; discussed leverage, cash flow, and leadership transition.

  • Keith Newton

    CEO announcing transition to Executive Chairman effective Nov. 1, 2026.

  • Matt DiCanio

    President and CFO; set to succeed Newton as CEO on Nov. 1, 2026.

Related articles

$CONHigh

Concentra Group Holdings Parent, Inc. Announces Results

Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE FOR IMMEDIATE RELEASE Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance Matt DiCanio to become president and CEO and Keith Newton to transition to executive chairman, effective Nov. 1, 2026

$PLTRHighAI 8/10

Mizuho reiterates Palantir stock rating on strong revenue growth

Mizuho reiterated an Outperform rating and $245 price target for Palantir (PLTR) after Q3 results showed 96% year-over-year revenue growth, exceeding estimates. U.S. Commercial revenue surpassed Government revenue for the first time. Management raised 2026 revenue growth guidance. Analysts praised Palantir's growth and margins, with several raising price targets.

$FNMedAI 8/10

B.Riley cuts Fabrinet stock price target on valuation concerns

B.Riley reduced its price target for Fabrinet (NYSE:FN) to $364 from $385, citing valuation concerns. Fabrinet reported Q1 sales of $1.475B and EPS of $4.34, beating estimates. Despite strong results, the stock is near its 52-week low. Fabrinet guided Q2 sales to $1.600B-$1.650B and EPS of $4.77-$4.92, above consensus. B.Riley adjusted its EBITDA estimates for 2027 and 2028.

$ONMed

B.Riley cuts ON Semiconductor stock price target on revised outlook

B.Riley reduced its price target for ON Semiconductor (NASDAQ:ON) to $97 from $105, maintaining a Buy rating. The firm cited the company's Q3 2026 results and Q4 guidance, which slightly exceeded estimates. ON Semiconductor reported strong AI data center sales growth and raised its 2026 and 2027 sales targets. The stock is currently undervalued relative to its Fair Value of $78.84, according to InvestingPro data.